Under the three-year award, the analytical consulting firm will compete against five other awardees for task orders in the JPEO-CBD Medical Domain, which have a cumulative value of as much as $495 million.
Work would include provision of technical expertise in microbiology, molecular biology, chemistry, bio-surveillance and engineering. It would also include program management in support in Department of Defense acquisition and FDA regulations for medical counter-measure development.
"The Tauri team is prepared to hit the ground running to assist JPEO-CBD in developing and fielding medical counter-measures," said Ben Hagar, Tauri Group's program manager. "Our involvement with the Department of Defense's Transformational Medical Technologies program is longstanding, and we are excited about the opportunity to extend our support across the broader medical domain."
JPEO-CBD is responsible for research, development, acquisition, fielding, and life cycle support of chemical and biological defense equipment and medical counter-measures.